- Trade $0 commission stocks & ETFs with as little as $1
- Earn up to $300 with qualifying deposits
- Discover new opportunities with Opto's AI-driven thematic investing system
- Theme and ETF screener
Pfizer (PFE) is a leading drug manufacturers - general business based in the US. It opened the day at $25.74 after a previous close of $25.23. During the day the price has varied from a low of $25.59 to a high of $26.10. The latest price was $25.73 (25 minute delay). Pfizer is listed on the NYSE and employs 88,000 staff. All prices are listed in US Dollars.
What's in this guide?
Our top picks for where to buy Pfizer stock
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options with no options contract fees
- Complimentary access to a financial planner
- Trade $0 commission stocks, ETFs, and options with as little as $1
- After-hours trading available
- Earn 4.5% interest on uninvested cash with Gold
- 24/7 customer support
How to buy Pfizer stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – PFE. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Pfizer stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Pfizer stock price (NYSE: PFE)
Use our graph to track the performance of PFE stocks over time.Pfizer shares at a glance
Open | $0.00 |
---|---|
High | $0.00 |
Low | $0.00 |
Close | $0.00 |
Previous close | $0.00 |
Change | $0.00 |
Change % | N/A% |
Volume | 0 |
52-week range | $24.11 - $31.06 |
---|---|
50-day moving average | $27.75 |
200-day moving average | $28.05 |
Wall St. target price | $32.60 |
PE ratio | 34.0946 |
Dividend yield | $1.67 (6.57%) |
Earnings per share (TTM) | $0.74 |
Is it a good time to buy Pfizer stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Pfizer price performance over time
Historical closes compared with the close of $25.73 from 2024-12-04
1 week (2024-12-02) | -0.35% |
---|---|
1 month (2024-11-08) | -3.71% |
3 months (2024-09-09) | -12.51% |
6 months (2024-06-07) | -9.97% |
1 year (2023-12-08) | -10.60% |
---|---|
2 years (2022-12-09) | -44.82% |
3 years (2021-12-09) | 45.4729 |
5 years (2019-12-09) | 29.3029 |
Is Pfizer stock undervalued or overvalued?
Valuing Pfizer stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Pfizer's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Pfizer's P/E ratio
Pfizer's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 34x. In other words, Pfizer shares trade at around 34x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Pfizer's PEG ratio
Pfizer's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.1802. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Pfizer's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Pfizer's EBITDA
Pfizer's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $18.4 billion.
The EBITDA is a measure of a Pfizer's overall financial performance and is widely used to measure a its profitability.
Pfizer financials
Revenue TTM | $59.4 billion |
---|---|
Operating margin TTM | 32.99% |
Gross profit TTM | $66.2 billion |
Return on assets TTM | 3.31% |
Return on equity TTM | 4.54% |
Profit margin | 7.16% |
Book value | $16.29 |
Market Capitalization | $143 billion |
TTM: trailing 12 months
Pfizer's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Pfizer.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Pfizer's total ESG risk score
Total ESG risk: 33.15
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Pfizer's overall score of 33.15 (as at 12/31/2018) is pretty weak – landing it in it in the 60th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Pfizer is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Pfizer's environmental score
Environmental score: 7/100
Pfizer's environmental score of 7 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that Pfizer is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Pfizer's social score
Social score: 18.47/100
Pfizer's social score of 18.47 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that Pfizer is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Pfizer's governance score
Governance score: 13.68/100
Pfizer's governance score puts it squarely in the 6th percentile of companies rated in the same sector. That could suggest that Pfizer is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Pfizer's controversy score
Controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Pfizer scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Pfizer hasn't always managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
Pfizer Inc was last rated for ESG on: 2019-01-01.
Total ESG score | 33.15 |
---|---|
Total ESG percentile | 60 |
Environmental score | 7 |
Environmental score percentile | 6 |
Social score | 18.47 |
Social score percentile | 6 |
Governance score | 13.68 |
Governance score percentile | 6 |
Level of controversy | 3 |
Pfizer share dividends
Dividend payout ratio: 65.12% of net profits
Recently Pfizer has paid out, on average, around 100% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Pfizer shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In Pfizer's case, that would currently equate to about $1.67 per share.
Pfizer's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
Pfizer's most recent dividend payout was on 1 December 2024. The latest dividend was paid out to all shareholders who bought their shares by 7 November 2024 (the "ex-dividend date").
Have Pfizer's shares ever split?
Pfizer's shares were split on a 1054:1000 basis on 16 November 2020 . So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1054 shares. This wouldn't directly have changed the overall worth of your Pfizer shares – just the quantity. However, indirectly, the new 5.1% lower share price could have impacted the market appetite for Pfizer shares which in turn could have impacted Pfizer's share price.
Pfizer share price volatility
Over the last 12 months, Pfizer's shares have ranged in value from as little as $24.1057 up to $31.0576. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Pfizer's is 0.615. This would suggest that Pfizer's shares are less volatile than average (for this exchange).
Pfizer overview
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.
Frequently asked questions
nullWhat percentage of Pfizer is owned by insiders or institutions?
Currently 0.048% of Pfizer shares are held by insiders and 67.814% by institutions. How many people work for Pfizer?
Latest data suggests 88,000 work at Pfizer. When does the fiscal year end for Pfizer?
Pfizer's fiscal year ends in December. Where is Pfizer based?
Pfizer's address is: 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 What is Pfizer's ISIN number?
Pfizer's international securities identification number is: US7170811035 What is Pfizer's CUSIP number?
Pfizer's Committee on Uniform Securities Identification Procedures number is: 717081103
More guides on Finder
-
Best Stocks for Beginners With Little Money to Invest
These are the stocks to buy when you don’t have much to spend.
-
7 Best Day Trading Apps of 2024
These are the best day trading apps, according to Finder’s comprehensive analysis.
-
Today’s Best Brokerage Account Bonuses [Signup and Transfer Promos]
Explore the best bonuses for opening a new brokerage account.
-
9 Best Discount Brokers of 2024 for Low-Cost Trading
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
-
5 best stock picking services of 2024
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
-
5 Top Graphene Stocks to Invest in Today
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
-
Ratings methodology for online brokers
Our star ratings for online brokerages are based on how they stack up in nine key categories.
-
How to gift stock
How do you gift stocks to loved ones? Learn the ins and outs of finding the right investments for them.
-
5 best ETFs for 2024
Check out the best-performing ETFs so far in 2024.
-
Acorns review 2024
Acorns is a financial service that rounds up your purchases and turns the extra change into investments.
Ask a question